A Phase 2 interventional study of Finerenone and Placebo in Premature Ovarian Insufficiency, sponsored by The University of Hong Kong-Shenzhen Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by The University of Hong Kong-Shenzhen Hospital · Phase 2, Interventional, and Treatment
This study is testing whether finerenone, a medicine currently used to protect the kidneys and heart, can help women with premature ovarian insufficiency (POI) grow ovarian follicles and produce eggs that can be collected for in vitro fertilization (IVF). Women with POI often have very few or no active egg-containing follicles, making it hard for them to conceive. About 46 women with POI will be randomly assigned, without either the participants or their doctors knowing the assignment, to take either finerenone or a matching placebo twice weekly for 24 weeks. Participants will be monitored regularly with ultrasound and blood tests. If follicle growth is observed, participants may undergo ovarian stimulation so that eggs or embryos can be collected and frozen. The main goal is to see whether more women in the finerenone group have eggs successfully retrieved during an IVF cycle, compared with the placebo group. The study will also look at other measures of ovarian reserve, egg and embryo quality, and pregnancy outcomes among participants who go on to embryo transfer.
181 studies on the registry are indexed under Primary Ovarian Insufficiency; 48 are open to participants now.
This study's planned enrollment of 46 is close to the median of 48 across 113 interventional studies indexed under Primary Ovarian Insufficiency.
Browse Primary Ovarian Insufficiency studies →The University of Hong Kong-Shenzhen Hospital is the lead sponsor of 16 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral finerenone 20 mg twice weekly for 24 weeks during the double-blind treatment phase.
Drug: Finerenone
Participants received matching placebo tablets, oral, twice weekly for 24 weeks during the double-blind treatment phase.
Drug: Placebo
Finerenone 20 mg oral tablet, administered twice weekly for 24 weeks.
Matching placebo tablet, oral, administered twice weekly for 24 weeks.
Proportion of Participants with Oocytes Retrieved During IVF Within 24 Weeks of Treatment
The proportion of participants who have oocytes aspirated during in vitro fertilization (IVF) within 24 weeks of starting study treatment.
Time frame: Within 24 weeks of treatment initiation
Antral Follicle Count (AFC)
Change in antral follicle count (AFC) measured by ultrasound from baseline, assessed during follow-up visits.
Time frame: Baseline and every 4 weeks up to 24 weeks of treatment
Anti-Mullerian Hormone (AMH)
Change in serum Anti-Mullerian Hormone (AMH) level from baseline, assessed during follow-up visits.
Time frame: Baseline and every 4 weeks up to 24 weeks of treatment
Serum Estradiol (E2) Level on Trigger Day
Serum estradiol (E2) level measured on the day of ovulation trigger during follicular development monitoring.
Time frame: On the day of ovulation trigger, within 24 weeks of treatment
Number of Total and Mature Oocytes Retrieved
Number of total oocytes and number of mature (MII) oocytes retrieved during IVF oocyte retrieval.
Time frame: At oocyte retrieval, within 24 weeks of treatment
Fertilization Rate
Proportion of retrieved oocytes that are successfully fertilized during IVF.
Time frame: Within 24 weeks of treatment initiation
Number of Embryos Formed
Number of embryos formed following fertilization of retrieved oocytes.
Time frame: Within 24 weeks of treatment initiation
Blastocyst Development Rate / High-Quality Embryo Rate
Proportion of embryos developing to blastocyst stage and/or classified as high-quality embryos.
Time frame: Within 24 weeks of treatment initiation
Clinical Pregnancy Rate
Proportion of participants with ultrasound-confirmed intrauterine gestational sac at approximately 6-7 weeks of gestation following embryo transfer.
Time frame: Approximately 6-7 weeks of gestation
Ongoing Pregnancy Rate
Proportion of participants with fetal cardiac activity confirmed by ultrasound at 8-10 weeks of gestation.
Time frame: 8-10 weeks of gestation
Live Birth Rate
Proportion of participants with delivery at or beyond 24 weeks gestation.
Time frame: At delivery (approximately 24-40 weeks gestation)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data collected during the study, including baseline characteristics, treatment allocation, ovarian reserve and ovarian function measures, treatment outcomes, and safety data, may be shared with qualified researchers upon reasonable request, subject to applicable ethical and data protection requirements.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Start: 12 months after publication of the primary results End: No end date
Access criteria: Qualified researchers + scientifically sound research + reasonable request + investigator/institutional review + ethical/privacy requirements
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Finerenone
Primary Ovarian Insufficiency →
The University of Hong Kong-Shenzhen Hospital